See more.
Know more.
Heal more.

Makoto is the only intravascular imaging platform that combines high-resolution structural views with plaque compositional analysis to deliver unprecedented treatment insights.

The YELLOW III Study (NCT04710368) demonstrated how 26 weeks of Evolocumab could reduce NIRS mxLCBI (-93.7) and IVUS PAV (-1.38%) in non culprit lesions in stable angina patients. View the study and watch Dr. Annapoorna Kini’s interview at the American College of Cardiology (ACC) 2023 Annual Scientific Sessions.

WATCH INTERVIEW